Jul 1 |
Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
|
Jul 1 |
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
|
May 13 |
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
|
May 10 |
Senti Biosciences GAAP EPS of -$0.26
|
May 9 |
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
|
Apr 30 |
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
|
Mar 21 |
Senti Biosciences GAAP EPS of -$0.42
|
Mar 21 |
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
|
Jan 5 |
Senti Biosciences to reduce workforce by 37%
|
Jan 5 |
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
|